Waters to buy Becton unit in a $17.5 billion deal amid tariff pressures https://t.co/9RTib9ueg0 https://t.co/9RTib9ueg0
An $18 bln health deal faces risks outside the lab https://t.co/vQWyT7FdAC
Auslaufende Patente und neue Technologien: Nach einer Flaute interessiert sich die Arzneimittelindustrie wieder verstärkt für kleine und große Übernahmen. https://t.co/jfuJEUPJpT
Waters Corporation, a lab equipment manufacturer, will merge with the Biosciences & Diagnostic Solutions business of Becton, Dickinson and Company (BDX) in a transaction valued at $17.5 billion. The deal, structured as a Reverse Morris Trust, involves a stock-and-cash exchange and aims to combine Waters' expertise in lab equipment with Becton's bioscience and diagnostics unit. This merger occurs amid ongoing macroeconomic uncertainties and tariff pressures affecting the health sector. Industry analysts note that while the deal strengthens the companies' positions in the medtech and biosciences fields, it also faces risks beyond laboratory operations. The transaction reflects renewed merger and acquisition momentum in the pharmaceutical and medical technology industries following a period of reduced activity.
